Invivyd doses first participants in phase 3 COVID-19 study evaluating antibody-vaccine co-administration
Invivyd (NASDAQ:IVVD) has initiated dosing in its LIBERTY Phase 3 clinical trial, a randomized, double-blind study designed to evaluate the safety, tolerability, and immunology of its investigational monoclonal antibody candidate, VYD2311, alone and co-administered with an mRNA COVID-19 vaccine in healthy adults.
The late-stage study plans to enroll approximately 210 healthy adult participants.
The clinical framework splits participants to evaluate three distinct cohorts: those receiving the monoclonal antibody alone, those receiving a traditional mRNA booster alone, and those receiving a simultaneous co-administration of both therapies.
The investigation aims to determine the comparative tolerability profile and clarify how antibody-mediated prevention interacts with standard vaccine regimens.
The LIBERTY trial is integrated into Invivyd's broader REVOLUTION clinical development program, which focuses on evaluating the potential medical benefits of monoclonal antibody prophylaxis for broad populations.
The REVOLUTION architecture also includes the pivotal DECLARATION trial, a large-scale Phase 3 study currently analyzing the preventive efficacy of VYD2311 against symptomatic COVID-19.
Depending on the trajectory of participant recruitment rates over the coming months, Invivyd targets the release of topline data from the LIBERTY trial in the third quarter of 2026.
The readout is scheduled to accompany the anticipated data release from the registration-enabling DECLARATION trial to support upcoming corporate regulatory filings.
